1
|
Sun B, Zhang T, Chen H, Gao W, Zhou J, Chen Y, Ding W, Yin X, Ren J, Hua C, Lin X. Microneedle delivery system with rapid dissolution and sustained release of bleomycin for the treatment of hemangiomas. J Nanobiotechnology 2024; 22:372. [PMID: 38918811 PMCID: PMC11201781 DOI: 10.1186/s12951-024-02557-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 05/16/2024] [Indexed: 06/27/2024] Open
Abstract
Hemangioma of infancy is the most common vascular tumor during infancy and childhood. Despite the proven efficacy of propranolol treatment, certain patients still encounter resistance or face recurrence. The need for frequent daily medication also poses challenges to patient adherence. Bleomycin (BLM) has demonstrated effectiveness against vascular anomalies, yet its use is limited by dose-related complications. Addressing this, this study proposes a novel approach for treating hemangiomas using BLM-loaded hyaluronic acid (HA)-based microneedle (MN) patches. BLM is encapsulated during the synthesis of polylactic acid (PLA) microspheres (MPs). The successful preparation of PLA MPs and MN patches is confirmed through scanning electron microscopy (SEM) images. The HA microneedles dissolve rapidly upon skin insertion, releasing BLM@PLA MPs. These MPs gradually degrade within 28 days, providing a sustained release of BLM. Comprehensive safety assessments, including cell viability, hemolysis ratio, and intradermal reactions in rabbits, validate the safety of MN patches. The BLM@PLA-MNs exhibit an effective inhibitory efficiency against hemangioma formation in a murine hemangioma model. Of significant importance, RNA-seq analysis reveals that BLM@PLA-MNs exert their inhibitory effect on hemangiomas by regulating the P53 pathway. In summary, BLM@PLA-MNs emerge as a promising clinical candidate for the effective treatment of hemangiomas.
Collapse
Affiliation(s)
- Bin Sun
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
| | - Tikai Zhang
- Institute of Nano and Biopolymeric Materials, School of Materials Science and Engineering, Tongji University, Shanghai, 201804, China
| | - Hongrui Chen
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
| | - Wei Gao
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
| | - Jingwei Zhou
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
| | - Yuxi Chen
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
| | - Wang Ding
- Department of Orthopaedic Surgery, Minhang Hospital, Fudan University, 170 Xin Song Road, Shanghai, 201100, China
| | - Xiaofan Yin
- Department of Orthopaedic Surgery, Minhang Hospital, Fudan University, 170 Xin Song Road, Shanghai, 201100, China
| | - Jie Ren
- Institute of Nano and Biopolymeric Materials, School of Materials Science and Engineering, Tongji University, Shanghai, 201804, China.
| | - Chen Hua
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
| | - Xiaoxi Lin
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
| |
Collapse
|
2
|
Cohen-Cutler S, Detterich JA, Miller JM, Anselmo DM, Luu M, Mascarenhas L. Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure. Pediatr Blood Cancer 2022; 69:e29934. [PMID: 36094157 DOI: 10.1002/pbc.29934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 07/18/2022] [Accepted: 08/01/2022] [Indexed: 11/08/2022]
Abstract
Infantile hemangioma is the most common soft tissue tumor of infancy. Extensive organ involvement is rare. This report describes an infant with biopsy confirmed infantile hemangioma with diffuse organ involvement causing anemia and failure to thrive. Treatment was initiated with propranolol and led to initial improvement; however, course was complicated by several episodes of respiratory failure secondary to pulmonary edema. Propranolol therapy was interrupted for several months while patient was maintained on a diuretic regimen and treated with vincristine and high-dose corticosteroids. Patient was transitioned back to propranolol and is clinically thriving with objective improvement on radiographic imaging.
Collapse
Affiliation(s)
- Sally Cohen-Cutler
- Cancer and Blood Disease Institute, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA.,Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Jon A Detterich
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.,Heart Institute, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA
| | - Joseph M Miller
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.,Department of Radiology, Children's Hospital Los Angeles, Los Angeles, California, USA
| | - Dean M Anselmo
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.,Division of Pediatric Surgery, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, California, USA
| | - Minnelly Luu
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.,Department of Dermatology, Children's Hospital Los Angeles, Los Angeles, California, USA
| | - Leo Mascarenhas
- Cancer and Blood Disease Institute, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA.,Keck School of Medicine, University of Southern California, Los Angeles, California, USA
| |
Collapse
|